Marshall Wace’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-43,500
| Closed | -$2.53M | – | 2607 |
|
|
2024
Q3 | $2.53M | Buy |
43,500
+21,123
| +94% | +$1.23M | ﹤0.01% | 1190 |
|
|
2024
Q2 | $1.02M | Sell |
22,377
-250,594
| -92% | -$11.5M | ﹤0.01% | 1521 |
|
|
2024
Q1 | $18.1M | Buy |
272,971
+223,499
| +452% | +$14.8M | 0.03% | 476 |
|
|
2023
Q4 | $1.97M | Buy |
+49,472
| New | +$1.97M | ﹤0.01% | 1020 |
|
|
2023
Q3 | – | Sell |
-62,650
| Closed | -$2.52M | – | 2112 |
|
|
2023
Q2 | $2.52M | Sell |
62,650
-53,870
| -46% | -$2.16M | ﹤0.01% | 1065 |
|
|
2023
Q1 | $4.98M | Buy |
116,520
+110,120
| +1,721% | +$4.7M | 0.01% | 851 |
|
|
2022
Q4 | $307K | Buy |
+6,400
| New | +$307K | ﹤0.01% | 1976 |
|
|
2022
Q3 | – | Sell |
-52,934
| Closed | -$1.46M | – | 2831 |
|
|
2022
Q2 | $1.46M | Buy |
52,934
+45,466
| +609% | +$1.26M | ﹤0.01% | 1719 |
|
|
2022
Q1 | $406K | Buy |
7,468
+1,741
| +30% | +$94.7K | ﹤0.01% | 2179 |
|
|
2021
Q4 | $335K | Sell |
5,727
-43,909
| -88% | -$2.57M | ﹤0.01% | 2323 |
|
|
2021
Q3 | $1.96M | Buy |
49,636
+37,581
| +312% | +$1.49M | 0.01% | 1238 |
|
|
2021
Q2 | $512K | Buy |
12,055
+6,178
| +105% | +$262K | ﹤0.01% | 1657 |
|
|
2021
Q1 | $362K | Sell |
5,877
-11,615
| -66% | -$715K | ﹤0.01% | 1756 |
|
|
2020
Q4 | $1.23M | Buy |
+17,492
| New | +$1.23M | 0.01% | 1018 |
|